April 25, 2013
On April 24, 2013, FDA approved revisions to the Prezista (darunavir) tablet and oral suspension label to update labeling with 48 week data from study TMC114-C228 for HIV-1 treatment experienced pediatric patients three to less than 6 years of age. The 48 week data is reflected in the Indications and Usage section and the following sections.
Section 6 Adverse Reactions
Clinical ADRs to PREZISTA/ritonavir (all grades, greater than or equal to 5%), were diarrhea (24%), vomiting (19%), rash (19%), abdominal pain (5%) and anorexia (5%).
Section 12 Clinical Pharmacology
Table 13 was updated to include the pharmacokinetic results from Study TMC114-C228
The proportion of subjects with HIV-1 RNA less than 50 copies/mL at Week 48 was 71%. The mean change in CD4+ percentage from baseline was 4%. The mean increase in CD4+ cell count from baseline was 187 x 106 cells/L.
The revised label will be made available at Drugs@FDA.
Prezista is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. PREZISTA is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents.
Prezista is a product of Janssen Pharmaceuticals, Inc.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.